|Bid price||117.75||Open price||119.75|
|Ask price||118.50||Prev close||118.50|
Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.
Register now for FREE Vectura Group share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B01D1K48|
|Activites||Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.||Index||n/a|
|Latest Share Price (p)||118.50||Net Gearing (%)||-0.13|
|Market Capitalisation (£m)||474.42||Gross Gearing (%)||26.40|
|Shares in issue (m)||402.46||Debt Ratio||22.10|
|P/E Ratio||-168.40||Debt-to-Equity Ratio||0.79|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.36|
|Dividend Yield (%)||0.00||Price to book value||2.09|
|Dividend cover (x)||0.00||ROCE||-0.03|
|Earning per share (p)||-0.70||EPS Growth (%)||61.11|
|52 week high / low||171.50 / 101.00||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
|08/07/2014||BUY||Dr Christopher Blackwell||CEO||1,212|
|08/07/2014||BUY||Dr Trevor Phillips||ED||1,212|
/* */ RNS Number : 4890U Vectura Group plc 16 October 2014 Vectura Group plc BLOCK LISTING RETURN Date: 16 October 2014 Name of applicant: Vectura Group plc Block Listing Return for the...
Vectura partner, Sandoz, has been granted marketing authorisation by the Portuguese Health Authority (Infarmed) for AirFlusal Forspiro,an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The receipt of the Portugese marketing authorisation by...
/* */ RNS Number : 8909T Vectura Group plc 09 October 2014 Vectura Group plc Approval in Portugal for innovative respiratory inhaler AirFluSal ® Forspiro ® · Portuguese Health...
Register now for FREE Vectura Group company news